Role of Antifungal Prophylaxis in Elderly Patients With Acute Myeloid Leukemia During Consolidation Therapy
Launched by UNIVERSITY OF ROME TOR VERGATA · Apr 20, 2024
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how antifungal medications can help prevent a serious fungal infection called invasive aspergillosis (IA) in older patients with acute myeloid leukemia (AML) who are undergoing a specific type of chemotherapy known as consolidation therapy. The researchers want to understand if using these antifungal treatments can reduce the chances of patients developing IA, especially since previous studies have shown that older patients are at higher risk for this infection during treatment.
To participate in this study, individuals must be over 60 years old and be receiving a chemotherapy regimen that includes high doses of a drug called cytarabine. Participants will need to provide written consent to join the study. Throughout the trial, patients can expect to be monitored closely for any signs of IA and to receive the antifungal medications if they qualify. This research aims to improve the care of elderly patients with AML by identifying effective ways to prevent infections during their treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Signed written informed consent according to ICH/EU/GCP and national/local laws
- • Patients aged older than 60 years underwent to consolidation course with intermediate/high doses of cytarabine
- Exclusion Criteria:
- • • Diagnosis of IA during induction course and previous antifungal treatment
About University Of Rome Tor Vergata
The University of Rome Tor Vergata is a prestigious academic institution recognized for its commitment to advancing medical research and education. As a clinical trial sponsor, it leverages its extensive resources and expertise in various fields of health sciences to foster innovative research initiatives. The university collaborates with healthcare professionals, researchers, and industry partners to conduct rigorous clinical trials aimed at improving patient care and outcomes. With a focus on ethical standards and scientific integrity, the University of Rome Tor Vergata is dedicated to contributing to the global body of medical knowledge and translating research findings into practical applications for the benefit of society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Roma, Rm, Italy
Patients applied
Trial Officials
Maria Ilaria Del Principe
Principal Investigator
University of Rome Tor Vergata
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported